Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Because EBI is expressed on the major subsets
2019-12-10

Because EBI2 is expressed on the major subsets of immune cells, and small molecule antagonists for EBI2 were recently described (Benned-Jensen et al., 2013, Gessier et al., 2014), EBI2 constitutes a tempting drug target reminiscent of the sphingosine-1-phosphate receptor superagonist fingolimod/Gile
-
Immune Response and Immune Evasion Up to
2019-12-10

Immune Response and Immune Evasion Up to 10% of the host Aloperine mg are infected with EBV during acute infectious mononucleosis. Most of these cells are effectively cleared by the immune system, but some downregulate viral gene expression and differentiate into safety in the resting memory B cel
-
The HEV vaccine developed based
2019-12-10

The HEV vaccine, developed based on p239 particles, is of good efficacy, immunogenicity and safety, and was licensed in China in 2012. p239 (aa 368–606) and E2 (aa 394–606) share a common region of ORF2, referred to as E2s (aa 459–606), which harbors the major antigenic determinants of the HEV vacci
-
The first hint that GLP might
2019-12-10

The first hint that GLP-1 might not be completely stable came from a meeting abstract in 1992, reporting that GLP-1 could be degraded in plasma incubations [16], although the enzyme(s) involved was not identified. A year later, Mentlein and colleagues [17], in a search for peptide substrates of the
-
The pseudo DUBs KIAA and Abraxas are required for
2019-12-10

The pseudo DUBs KIAA0157 and Abraxas are required for the catalytic function of BRCC36. Comparison of the BRCC36–KIAA0157 heterodimer structure with an inactive BRCC36 homodimer structure provides a model for understanding how this functional interplay is achieved. As shown in schematic form in Figu
-
br Introduction The allergic response is a complex process i
2019-12-10

Introduction The allergic response is a complex process involving the interaction of several mediators; among these, cysteinyl leukotrienes (CysLTs) represent one of the most important actors in the pathogenesis of airway allergic diseases such as allergic rhinitis and asthma [1]. Pharmacological
-
br Acknowledgments br Introduction Cysteinyl leukotrienes Cy
2019-12-10

Acknowledgments Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic Darunavir Ethanolate and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pr
-
Acidic substituents showed moderate biochemical activity but
2019-12-10

Acidic substituents () showed moderate biochemical activity, but these compounds showed reduced cellular potency. Additional compounds bearing a carboxylic NBI 27914 hydrochloride were also prepared and tested (data not shown). All of acidic compounds showed low cellular potency regardless of their
-
br Third trimester crossing the threshold
2019-12-10

Third trimester – crossing the threshold to immunocompetence Summary Regrettably, studies on the fetal immune system have yet to yield practical results. While it is becoming apparent that the fetal immune response plays a role in determining the outcome of congenital CMV infection, we still l
-
Soon after the discovery of
2019-12-10

Soon after the discovery of ET1 and the cloning of its ETA and ETB receptors, low-molecular-weight compounds were identified that can prevent the binding and effects of radioactively labeled ET1 3, 5, 6, 8. Initially, these ERAs resulted from screening efforts (e.g. BQ123 39, 49 and bosentan [50]).
-
Among our patients with anti enolase drusen those
2019-12-10

Among our patients with anti-enolase drusen, those with a relatively short duration from the onset of visual symptoms to the first visit tended to have normal structure of photoreceptors with preserved visual function, despite the presence of drusen-related RPE abnormalities (Cases 1-3 and 8). In co
-
In general we observed that the enolase gene
2019-12-10

In general, we observed that the enolase gene with highest mRNA levels was TVAG_043500, under all three iron concentration conditions. mRNA levels for this gene are very similar in normal and iron rich cultures (73.9 and 78.1 fold change, respectively), and higher in iron depleted cultures (118.3 fo
-
E protein was studied using specific anti E antibodies
2019-12-10

E1 protein was studied using specific anti-E1 Voreloxin Hydrochloride synthesis in wild type cells and in transfected cells overexpressing the enzyme. The results revealed several unusual characteristics, which are unique to this ubiquitin-activating enzyme. The E1 was translated as a full-length pr
-
NF B is a family of protein mediators that
2019-12-09

NF-κB is a family of protein mediators that regulate various innate and adaptive immune responses [29,30]. The NF-κB family consists of the following five proteins: c-Rel (Rel); p65 (RelA); RelB; p50(NF-κB1); and p52(NF-κB2). It has been confirmed that NF-κB is activated by TNF family cytokines, suc
-
Recently roflumilast has been approved as the first
2019-12-09

Recently, roflumilast has been approved as the first selective PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD) [2]. Roflumilast has been suggested to target several different pathogenetic mechanisms, including inflammation, fibrotic, emphysematous and vascular remode
14133 records 893/943 page Previous Next First page 上5页 891892893894895 下5页 Last page